Aeglea Biotherapeutics Inc. (NASDAQ:AGLE) shares were down 2.1% on Monday . The stock traded as low as $4.05 and last traded at $4.12, with a volume of 54,628 shares. The stock had previously closed at $4.21.

Several research analysts recently weighed in on AGLE shares. Needham & Company LLC started coverage on shares of Aeglea Biotherapeutics in a report on Monday, May 9th. They issued a “buy” rating and a $18.00 target price for the company. BMO Capital Markets started coverage on shares of Aeglea Biotherapeutics in a report on Monday, May 2nd. They issued an “outperform” rating and a $19.00 target price for the company. Finally, Wells Fargo & Co. started coverage on shares of Aeglea Biotherapeutics in a report on Monday, May 2nd. They issued an “outperform” rating for the company.

The firm has a 50-day moving average of $5.89 and a 200 day moving average of $7.37. The stock’s market capitalization is $55.25 million.

Aeglea Biotherapeutics (NASDAQ:AGLE) last issued its earnings results on Friday, May 20th. The company reported ($7.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by $6.68. On average, analysts expect that Aeglea Biotherapeutics Inc. will post ($2.35) earnings per share for the current fiscal year.

Aeglea BioTherapeutics, Inc is a biotechnology company. The Company is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. Its engineered human enzymes are designed to degrade specific amino acids in the blood.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.